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Abstract Lung cancer is the leading cause of cancer-related
deaths worldwide. The case-fatality rate of lung cancer re-
mains exceptionally high at 95% despite numerous medical
advancements in therapeutic strategies in the last decades.
However, patients diagnosed at Stage I are commonly curable
and have a 5-year survival rate of 50–80%. Unfortunately,
delayed diagnosis of lung cancer has been unavoidable and
is an important factor in the overall outcome of treatment.
Accordingly, screening of high-risk individuals is likely to
have hugely beneficial outcomes for patient survival.
Current screening approaches include low-dose computed to-
mography and chest X-ray. Recently, alternative approaches
for lung cancer screening have been developed including anal-
ysis of biomarkers, including DNA, RNA, proteins, and anti-
bodies in blood, sputum, bronchoalveolar lavage (BAL), and
breath. Biomarker analysis would also provide critical infor-
mation regarding tumor growth pattern, cells of origin of
tumor, subtype of lung cancer, and/or drugmetabolism as well
as monitor patient prognosis. Novel non-invasive lung cancer
diagnostic strategies could improve and complement the suc-
cess of CT-scan and chest X-ray.
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Introduction
Lung cancer is a highly prevalent disease and is the foremost
cause of cancer-related deaths worldwide, i.e., 25% of cancer-
related deaths [1]. In 2012, it accounted for approximately 1.6
million deaths, which means more deaths than three well-
known cancer types put together such as, breast, prostate,
and colorectal cancers. Themortality rate of lung cancer close-
ly parallels the incidence pattern resulting in an extremely
high-case fatality rate of 95%. The persistently low patient
survival is reflected in a 5-year survival rate of 15–17% [1,
2]. Epidemiological observations performed across varied de-
mographic cohorts in India point towards a similar pattern of
incidence and mortality, underlining the significant burden of
lung cancer towards mortality and morbidity in India [3, 4].
The GLOBOCAN 2012 report estimated lung cancer inci-
dence in India to be 70,275 (6.9%) across all ages and both
sexes, and the estimation was 63,759 (9.3%), making it the
third most common cause of cancer-related mortality in India
after breast and cervical cancers (Fig. 1) [5]. However, it is
speculated that the illustrated incidence and mortality patterns
represent an underestimation of the overall lung cancer burden
due to the quality of data acquired from regional hospital-
based registries. According to the report of the National
Cancer Registry Programme, there is significant (rise in) lung
cancer incidence in Delhi, Chennai, and Bengaluru in both
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